Axogen, Inc. (AXGN)

Market Cap	567.71M
Revenue (ttm)	180.86M
Net Income (ttm)	-14.31M
Shares Out	44.01M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	58.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,772
Open	12.71
Previous Close	12.75
Day's Range	12.48 - 12.98
52-Week Range	5.55 - 15.90
Beta	1.13
Analysts	Strong Buy
Price Target	15.00 (+16.28%)
Earnings Date	Nov 7, 2024

About AXGN

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Karen Zaderej
• Employees: 428
• Stock Exchange: NASDAQ
• Ticker Symbol: AXGN
• Website: https://www.axogeninc.com

Financial Performance

In 2023, Axogen's revenue was $159.01 million, an increase of 14.74% compared to the previous year's $138.58 million. Losses were -$21.72 million, -24.98% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 16.28% from the latest price.

Price Target

$15.0

(16.28% upside)

Analyst Consensus: Strong Buy